Written by: the Medetone Medical Team
Medically reviewed by: Dr Abdullah
Reading time: 8 minutes · Guidance verified: October 2026
Ozempic has become one of the most discussed medicines of recent years, and also one of the most misunderstood. Much of the confusion comes from a single fact that is widely skipped: what Ozempic is licensed for is not the same as what people talk about using it for. This guide explains what the medicine is, how it works in the body, what the clinical evidence shows, and where it sits relative to the licensed weight-management options. It is informational and does not replace advice from your doctor.
The essentials
Active ingredient: semaglutide, a GLP-1 receptor agonist
Licensed for: type 2 diabetes
Administered: weekly subcutaneous injection
For weight management: a different semaglutide product is licensed
Prescription-only and requires clinical assessment
What Ozempic is
Ozempic is a brand name for semaglutide, a medicine in the class known as GLP-1 receptor agonists.
GLP-1, or glucagon-like peptide-1, is a hormone your intestine produces naturally after eating. It signals the pancreas to release insulin, tells the liver to reduce glucose production, slows the stomach’s emptying and acts on appetite centres in the brain. Semaglutide mimics that hormone, but with a far longer duration of action, which is why it is given as a once-weekly injection rather than responding meal by meal.
So the short answer to what is Ozempic is that it is a synthetic version of a hormone your body already makes, designed to last long enough that one dose covers a week.
What it is licensed for, and why that matters
This is the part most articles gloss over, and it is the most important thing to understand.
Ozempic is authorised for the treatment of type 2 diabetes. That is the indication it was developed for, trialled for and licensed for.
Weight loss occurs as part of how the medicine works, because appetite reduction is one of its mechanisms. But experiencing weight loss as an effect is not the same as being licensed for weight management.
For weight management specifically, a different semaglutide product is licensed, marketed as Wegovy and provided at higher doses. Same molecule, different dosing, different indication, different clinical trial programme behind it. Our guide comparing Wegovy and Ozempic sets out exactly how they differ.
This distinction matters practically. It determines which product a clinician can appropriately prescribe for your situation, what dose range applies, and what evidence supports the outcome you are hoping for.
How it works in the body
Four mechanisms operate together.
Insulin release when glucose is high. Semaglutide stimulates insulin secretion specifically when blood glucose is elevated, rather than continuously. This is why it carries a lower risk of hypoglycaemia than some older diabetes medicines.
Reduced glucose production by the liver. The liver releases stored glucose between meals. Semaglutide reduces that output.
Slower gastric emptying. Food stays in the stomach longer, which both flattens post-meal glucose spikes and prolongs fullness.
Action on appetite centres. Semaglutide acts on the hypothalamus, reducing the drive to eat. People report feeling full sooner, snacking less, and experiencing less of the constant mental preoccupation with food that many describe as the most significant change.
What the clinical evidence shows
The SUSTAIN trial programme evaluated semaglutide in more than 7,000 people with type 2 diabetes. Three findings stand out, all measured at 56 weeks.
Glycaemic control. HbA1c reductions of 1.0% to 1.8%, with 66% to 79% of participants reaching an HbA1c below 7%. Importantly, that control was sustained rather than fading, with most participants retaining the benefit beyond the first year.
Cardiovascular outcomes. SUSTAIN-6 found a 26% reduction in major cardiovascular events, meaning heart attack, stroke and cardiovascular death. That matters because cardiovascular disease is the leading cause of death in people with type 2 diabetes.
Weight. Average weight loss of 4 to 6 kg in people with type 2 diabetes at the doses used in these trials. Worth noting that weight-management trials of semaglutide at higher doses report considerably larger figures, which is part of why a separate higher-dose product exists for that indication.
Semaglutide also improves systolic blood pressure and LDL cholesterol, contributing to a better overall cardiovascular risk picture.
How it is taken
Dosing escalates gradually, specifically to reduce gastrointestinal side effects.
A typical schedule starts at 0.25 mg weekly for four weeks, purely to establish tolerance rather than for therapeutic effect. It then moves to 0.5 mg weekly for at least four weeks, before settling at a 1 mg weekly maintenance dose. Where glycaemic targets are not met, 2 mg weekly may be used.
Your prescriber determines the right dose based on your response and goals. Dose should never be adjusted independently, since rushing the schedule is the most common cause of poor tolerance.
Side effects
Most side effects are gastrointestinal and most improve over time.
Nausea is the most common, reported by roughly 15% to 20% of people, and is most pronounced when starting or increasing the dose. Diarrhoea affects around 8% to 10%, with constipation and abdominal pain each affecting around 5% to 7%.
Eating smaller portions and escalating the dose slowly are the two things that help most. Overeating while taking semaglutide tends to produce discomfort and nausea directly, which is itself a signal to reduce portion size.
Less common effects include headache, fatigue and dizziness during dose increases, and generally mild injection site reactions. Rarer but more serious concerns include pancreatitis, and gallbladder problems can develop during rapid weight loss.
One point on labelling: thyroid-related warnings differ between regions, with United States labelling and European product information treating them differently. If you have a personal or family history of thyroid cancer, or any thyroid condition, raise it specifically with your prescriber and check the product information applicable where you are.
Muscle loss and body composition
This is under-discussed and genuinely important.
Rapid weight loss by any method costs lean mass as well as fat. With GLP-1 medicines, estimates suggest a substantial proportion of weight lost, commonly put in the region of 25% to 40%, may come from lean tissue.
That matters because muscle drives resting metabolic rate. Losing it lowers the rate at which you burn energy, which makes weight harder to maintain afterwards, and it reduces strength and physical function.
Two things protect against it: adequate protein intake and resistance training. Both are strongly recommended alongside treatment rather than optional extras. Our guide to protein during treatment covers targets in detail.
Facial changes
The phrase “Ozempic face” describes the loss of facial volume some people notice during rapid weight loss. Reduced fat in the cheeks can create a hollowed appearance, and skin laxity may develop when weight comes off quickly.
This is a consequence of losing fat, not a direct drug effect, and the same thing happens with rapid weight loss by any route. People who are naturally thin-faced tend to notice it more. Gradual weight loss reduces the severity, which is another argument against rushing the dose schedule, and adequate protein supports tissue quality throughout.
What happens if you stop
Weight regain after stopping is common, and this is worth understanding before starting rather than after.
These medicines work while they are being taken. When treatment stops, appetite signalling returns to its previous state. Without the lifestyle changes built during treatment, weight tends to return. Our guide on stopping weight-loss medication covers what to expect.
This is why clinicians frame these as long-term treatments with periodic review rather than short courses, and why the habits built during treatment matter as much as the medicine itself.
If weight management is what you are looking for
Many people arrive at the question what is Ozempic because they are considering treatment for weight rather than diabetes. If that describes you, the useful next step is a proper assessment rather than deciding on a specific product.
A clinician will consider your medical history, current medicines, BMI and any weight-related conditions, then determine whether treatment is appropriate and which licensed option fits. Prescription weight-management treatment is typically considered for adults with a BMI of 30 or above, or 27 or above with a weight-related condition such as high blood pressure, type 2 diabetes or sleep apnoea.
At Medetone, eligible patients can complete a clinical assessment to establish whether a weight-management treatment is suitable. You can read about Wegovy and Mounjaro, or see all weight-loss treatments. Patients in the UK can access care through Medetone UK or our partner service Rightangled, and in the United States through Medetone US.
Treatment is not appropriate for everyone, and an honest assessment will tell you that where it applies.
When to speak to a doctor
Seek medical advice promptly if you experience severe abdominal pain that does not settle, nausea or vomiting preventing you from eating, recurrent hypoglycaemia with symptoms such as sweating, trembling or confusion, worsening injection site reactions, or sudden visual changes.
Regular review during treatment is standard, allowing side effects to be identified and the dose adjusted appropriately.
Frequently asked questions
What is Ozempic used for?
It is licensed for type 2 diabetes. A separate, higher-dose semaglutide product is licensed for weight management.
Is Ozempic the same as Wegovy?
Same active ingredient, semaglutide, but different doses and different licensed indications.
How quickly does it work?
Glucose reductions begin within the first weeks. Maximum effect on HbA1c and weight is generally seen between four and six months.
Will I regain weight if I stop?
Commonly, yes. Appetite signalling returns to baseline when treatment stops, which is why it is managed as a long-term treatment.
Can I get it without a prescription?
No. It is prescription-only and requires clinical assessment. Purchasing from unverified sources carries genuine safety risk.
In summary
What is Ozempic comes down to this: it is semaglutide, a GLP-1 receptor agonist licensed for type 2 diabetes, given as a weekly injection. It works by prompting insulin release when glucose is high, reducing liver glucose output, slowing digestion and reducing appetite. The evidence shows meaningful glycaemic control, a 26% reduction in major cardiovascular events, and moderate weight loss. For weight management specifically, a different licensed product exists, and which one suits you is a clinical decision rather than a consumer choice.
Medical information: this article is for information only and does not replace diagnosis, prescription or medical advice. Ozempic is a prescription-only medicine. Treatment is subject to consultation, eligibility and clinical approval. Individual results vary.
References:
AEMPS, Agencia Española de Medicamentos y Productos Sanitarios: https://www.aemps.gob.es
CIMA, Centro de Información de Medicamentos (Spain): https://cima.aemps.es
Ministerio de Sanidad (Spain): https://www.sanidad.gob.es
European Medicines Agency, Ozempic: https://www.ema.europa.eu/en/medicines/human/EPAR/ozempic
European Medicines Agency, Wegovy: https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy
AIFA, Agenzia Italiana del Farmaco: https://www.aifa.gov.it
ANSM (France): https://ansm.sante.fr
BfArM (Germany): https://www.bfarm.de
